Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target.
- Under the terms of the agreement, Olema will make an upfront licensing payment
- Under the terms of the agreement, Olema will make an upfront licensing payment
- Under the terms of the agreement, Olema will make an upfront licensing payment
- Under the terms of the agreement, Olema will make an upfront licensing payment
- Under the terms of the agreement, Olema will make an upfront licensing payment
- Under the terms of the agreement, Olema will make an upfront licensing payment
- Under the terms of the agreement, Olema will make an upfront licensing payment
Under the terms of the agreement, Olema will make an upfront licensing payment
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target.
Under the terms of the agreement, Olema will make an upfront licensing payment
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target.
Under the terms of the agreement, Olema will make an upfront licensing payment
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target.
Under the terms of the agreement, Olema will make an upfront licensing payment
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target.
Under the terms of the agreement, Olema will make an upfront licensing payment
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target.
Under the terms of the agreement, Olema will make an upfront licensing payment
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target.